increased bioactivity, an increased margin of safety, predictability and straightforwardness of pharmacokinetics and pharmacodynamics and ease of formulation. In the case of the sEH/COX-2 inhibitor additional advantages include reduction of side effects of COX inhibitors such as disturbance of prostacyclin to thromboxane ratio and improving safety of COX inhibitors by reducing the required dose for effectiveness. Thus these dual inhibitors may replace COX-2 selective compounds for the treatment of inflammatory conditions.
